Haemonetics Corporation provided revenue guidance for the fiscal year 2025. For the year, the company expects GAAP total reported revenue growth to be between 5% to 8%, and total organic revenue growth to be between 0% to 3%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
88.64 USD | -1.61% | -6.50% | +3.66% |
05-23 | Haemonetics Prices Upsized Private Placement of $600 Million Convertible Senior Notes | MT |
05-21 | Haemonetics Insider Sold Shares Worth $254,443, According to a Recent SEC Filing | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.66% | 4.51B | |
-5.31% | 181B | |
-1.21% | 108B | |
-5.53% | 66.57B | |
+1.22% | 49.95B | |
+7.03% | 43.84B | |
+4.91% | 41.71B | |
+21.96% | 31.59B | |
+14.45% | 25.3B | |
-4.81% | 23.83B |
- Stock Market
- Equities
- HAE Stock
- News Haemonetics Corporation
- Haemonetics Corporation Provides Revenue Guidance for the Fiscal Year 2025